Paradoxical High-Level Spiramycin Resistance and Erythromycin Susceptibility Due to 23S rRNA Mutation in *Streptococcus constellatus*

Agathe Capitaine, Paul-Louis Woerther, Michel Auzou, Elisabeth Chachaty, François Guerin, Jean-Christophe Giard, Vincent Cattoir, Christophe Isnard

► To cite this version:

Agathe Capitaine, Paul-Louis Woerther, Michel Auzou, Elisabeth Chachaty, François Guerin, et al.. Paradoxical High-Level Spiramycin Resistance and Erythromycin Susceptibility Due to 23S rRNA Mutation in *Streptococcus constellatus*. *Microbial Drug Resistance*, 2020, 26 (7), pp.727-731. 10.1089/mdr.2019.0288 . hal-02569879

HAL Id: hal-02569879

<https://hal-normandie-univ.archives-ouvertes.fr/hal-02569879>

Submitted on 9 Jun 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Paradoxical high-level spiramycin resistance and erythromycin susceptibility due to 23S rRNA mutation in *Streptococcus constellatus*

Agathe Capitaine¹, Paul-Louis Woerther², Michel Auzou¹, Elisabeth Chachaty³, François Guérin^{1,4}, Jean-Christophe Giard⁵, Vincent Cattoir^{6,7} and Christophe Isnard^{1,4,*}

Running title: Paradoxical MLS resistance due to 23S rRNA mutation in *Streptococcus constellatus*

Normandie Univ, UNICAEN, CHU de CAEN Normandie, Service de Microbiologie, 14000 Caen, France¹; Unité de Bactériologie-Hygiène, Département de Microbiologie, Assistance Publique - Hôpitaux de Paris, Hôpital Henri Mondor, Créteil, France²; Service de Microbiologie, Institut Gustave Roussy APHP, Villejuif, France³; Normandie Univ, UNICAEN/UNIROUEN, EA2656 GRAM2.0, 14000 Caen, France⁴; Normandie Univ, UNICAEN, EA4655 U2RM, 14000 Caen, France⁵; Centre Hospitalier Universitaire de Rennes, Site Pontchaillou, 35000 Rennes, France⁶; CNR de la Résistance aux Antibiotiques, Laboratoire Associé « Entérocoques et résistances particulières chez les bactéries à Gram positif », 35000 Rennes, France⁷.

***Correspondance** : Mailing address: Dr. Christophe ISNARD, Service de Microbiologie, CHU de CAEN, 14033 Caen Cedex, France.

E-mail: isnard-c@chu-caen.fr

Keywords: *Streptococcus constellatus*; *Streptococcus milleri* group; MLS resistance; 23S rRNA mutation; A2062C; ARMS qPCR.

Word counts: Abstract: 253; Text: 1942; Tables: 2; Figures: 1; References: 19

Abstract

Objectives: The aim of the study was to characterize phenotypically and genotypically an uncommon mechanism of resistance to macrolides, lincosamides and streptogramins (MLS) in a *Streptococcus milleri* group clinical isolate.

Methods: The isolate UCN96 was recovered from an osteoradionecrosis wound, and was identified using the MALDI-TOF mass spectrometry and the partial sequencing of the *sodA* gene. Antimicrobial susceptibility testing (AST) were carried out by the disc diffusion method and MICs were determined by the broth microdilution technique. PCR screening was performed for MLS resistance genes described in Gram-positive bacteria. Specific mutations in the ribosomal proteins L3-, L4- and L22-encoding genes were also screened as well as those in domain V of the 23S rRNA gene (*rrl*). The number of mutated copies of the *rrl* gene was determined using ARMS (amplification-refractory mutation system) qPCR analysis.

Results: The clinical isolate UCN96 was unambiguously identified as *Streptococcus constellatus*. It was susceptible to all ML antibiotics except spiramycin (MIC >256 mg/L) while it was also resistant to streptogramins. Screening for all acquired resistance genes was negative while no mutation was found in genes coding for L3, L4 and L22 ribosomal proteins. Interestingly, a single mutation, A2062C (according to *Escherichia coli* numbering), was detected in the domain V of 23S rRNA.

Conclusion: Mutations at the position 2062 of 23S rRNA have been detected once in *S. pneumoniae*, and not yet in other *Streptococcus* spp. This mechanism is very

51 likely uncommon in Gram-positive bacteria since different copies of 23S rRNA
52 operons should be mutated for development of such a resistance pattern.

Introduction

Streptococcus constellatus belongs to the *Streptococcus milleri* group (SMG) besides two others species, *Streptococcus anginosus* and *Streptococcus intermedius*. SMG is part of the human microbiota and can be in the oral cavity as well as abdominal, urogenital and upper respiratory tracts ¹. Streptococci from the SMG are responsible for various pyogenic infections including cardiac, skin, abdominal and central nervous system infections ¹. These organisms are usually susceptible to many antimicrobial agents including those commonly used for infections caused by streptococci such as β -lactams, macrolides-lincosamides-streptogramins (MLS) and glycopeptides. Whereas there is no resistance to β -lactams and glycopeptides described in SMG, acquired MLS resistance has been reported, with approximately 17% of clinical isolates resistant to erythromycin and clindamycin ². In streptococci, MLS resistance is mediated by two major mechanisms which are target site modification and active drug efflux ³. Ribosomal alteration is caused by methylation of a specific adenine residue (the so-called A2058) of target site in the 23S rRNA and is mediated by an adenine-*N*6-methyltransferase encoded by a gene belonging to the *erm* class (erythromycin ribosome methylase). This methylation of the A2058 residue induces a conformational change in the 50S ribosomal subunit that alter the binding of antibiotics to the ribosome and causes the so-called MLS_B phenotype. The second mechanism consisted of an active efflux of the antibiotics encoded by the *mef* gene. This active efflux is responsible for unique resistance to 14- and 15-membered macrolides and confers the so-called M phenotype. Other mechanisms of MLS resistance have been rarely described in Gram-positive bacteria, such as other mutations in 23S rRNA or in L3, L4, L22 ribosomal proteins and to our knowledge, have not been yet described in the SMG ⁴⁻⁸.

The aim of this study was to decipher the molecular aspect of an atypical resistance phenotype in a clinical isolate of *S. constellatus* (UCN96).

(Part of this work was presented in the 14th European Congress of Clinical Microbiology and Infectious Diseases, EV0187, Copenhagen, 2015)

Materials & Methods

Bacterial strains used in the study

The UCN96 isolate was recovered in June 2014 from a osteoradionecrosis radionecrosis wound in a patient hospitalized at the Gustave Roussy Institute (Villejuif, France) for a tongue cancer medical history. The same bacterial strain was recovered from the patient in a chin outpouring in May 2014 but the antimicrobial susceptibility testing realized then, showed that the *S. constellatus* isolated was fully susceptible to all MLS antibiotics. In front of this statement, the patient has received pristinamycin at 1g twice in a day for 10 days since he was intolerant to β -lactams. The isolate UCN96 was identified by MALDI-TOF mass spectrometry (Microflex; Bruker Daltonics; Germany) and partial sequencing of the *sodA* gene as previously described⁹. *Staphylococcus aureus* ATCC 29213 and *Streptococcus pneumoniae* ATCC 49619 were used as antimicrobial susceptibility testing (AST) controls while an MLS-susceptible *S. constellatus* from our collection (*S. constellatus* 13422) was also tested as wild-type control for comparative purposes.

Antimicrobial susceptibility testing

Antimicrobial susceptibility testing was carried out by the disc diffusion method using Mueller-Hinton agar plates supplemented with lysed horse blood (5%) and β -NAD (20 mg/L) (bioMérieux; France) according to the Antibigram Committee of the French Society for Microbiology recommendations (CA-SFM/EUCAST; www.sfm-microbiologie.org). MICs of erythromycin, azithromycin, spiramycin, josamycin, telithromycin, lincomycin, clindamycin, pristinamycin, quinupristin-dalfopristin, quinupristin, dalfopristin and chloramphenicol were determined by the broth microdilution technique according to EUCAST guidelines (<http://eucast.org/>).

DNA preparation, PCR assays and gene sequencing.

DNA extraction was performed using the automated easyMAG® extractor (bioMérieux, France) according to the protocol suggested by the manufacturer. Extracted bacterial DNA was eluted with 25 µl elution buffer and stored at -20°C. PCR experiments for the detection of acquired genes putatively involved in MLS resistance [e.g. *erm*(A), *erm*(B), *erm*(C), *erm*(F), *erm*(TR), *erm*(T), *erm*(X), *msr*(A) and *mef*(A)] as well as uncommon acquired genes [*Inu*(A), *Inu*(B), *Inu*(C), *Inu*(E), *Isa*(A), *Isa*(B), *Isa*(C), *Isa*(E), *vat*(A), *vat*(B), *vat*(C), *vat*(D), *vat*(E), *vga*(A), *vga*(B), *vga*(C), *vga*(D), *vga*(E), *vgb*(A), *vgb*(B)] were carried out using an in-house method. The screening of point mutations was also performed by PCR-sequencing using specific primers (Sigma-Aldrich, France) (Table 1) allowing amplification of the L3, L4 and L22 ribosomal protein encoding genes (*rplC*, *rplD* and *rplV* genes respectively) and in the 23S rRNA (*rrl*) gene. Amplification refractory mutation system (ARMS) qPCR was used to distinguish if the mutation of *rrl* gene affected all the alleles harbored by the bacterial strain (e.g. 4 alleles in *S. constellatus* and all SMG) as previously described in eucaryotes^{10,11}. Primers used for qPCR ARMS experiment are detailed in Table 1. Briefly, two sets of primers were design. Oligonucleotide sequences of the forward primers were strictly complementary to the *rrl* region where the mutation was found. For one of the two forward primers, the nucleotide localized at the 3' end corresponded to the nucleotide found in the mutant strain sequence, whereas for the other, it corresponded to the nucleotide found in the wild type. The reverse primer was the same for the 2 experiments. ARMS qPCR experiments were made by real-time PCR using the SsoAdvanced universal SYBR green supermix kit and a CFX Connect real-time PCR detection system (Bio-Rad, France) according to manufacturer's recommendations. To determine if the mutation appeared in several

gene loci, a comparison of cycle threshold between the two sets of primers was analyzed for the mutated strain UCN96. A susceptible strain of our collection, *S. constellatus* 13422, was used as comparator. In case of higher initial amount of mutated DNA matrix, a lower CT value should be obtained. Then if a difference in CT values was observed between the 2 sets of primers, we should conclude that more than one allele was mutated. Conversely, the same result was expected in favor of the “wild-type” set of primers when using the *S. constellatus* 13244 DNA as template.

Multiple alignment, phylogenetic and gene analysis.

Genome of the annotated strain *S. constellatus* 1050 available at the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/genome/>) was used for comparative sequences analysis. 23S rRNA gene partial sequence was then compared to deposited sequences available from the BIBI site database (<https://umr5558-bibiserv.univ-lyon1.fr/lebibi/lebibi.cgi>). Sequence comparison by multiple alignment and phylogenetic analysis were performed using BioEdit Sequence Alignment Editor Software (<http://www.mbio.ncsu.edu/bioedit/bioedit.html>) and the neighbour-joining algorithm with the ClustalOmega software (<http://www.ebi.ac.uk/Tools/msa/clustalo/>).

Results

Bacterial Identification

The identification of strain UCN96 was carry out twice using the MALDI-TOF mass spectrometry technology and was unambiguously confirmed as *S. constellatus* by the partial *sodA* gene sequencing.

In vitro antimicrobial susceptibility testing

By the disc diffusion method, the strain UCN96 was susceptible to almost all tested antimicrobials: penicillin G, ampicillin, kanamycin, tobramycin, gentamicin, vancomycin, teicoplanin, levofloxacin, rifampicin, tetracycline, chloramphenicol and cotrimoxazole but in contrast, it exhibited an uncommon MLS resistance. After MIC determination, the strain appeared harbouring an *a priori* paradoxical MS_{AB} resistance phenotype. Indeed, the strain was susceptible to all 14- and 15-membered macrolides (e.g. erythromycin, telithromycin, and azithromycin, with MICs of 0.03, <0.008 and 0.12 mg/L, respectively), lincosamides (e.g. lincomycin and clindamycin, with MICs of 1 and 0.06 mg/L, respectively) and chloramphenicol with a MIC of 8 mg/L. On the other hand, it was highly-resistant to spiramycin or josamycin (16-membered macrolides) with MICs of >256 and 32 mg/L, respectively and streptogramins (MIC >64 mg/L; 8 mg/L, 4 mg/L and 8 mg/L for dalfopristin, quinupristin, quinupristin-dalfopristin and pristinamycin, respectively.) (Table 2). As compared to *S. constellatus* 13422 susceptible strain, UCN96 exhibited MICs of spiramycin, josamycin, dalfopristin, quinupristin, quinupristin-dalpristin and pristinamycin 4, 512, 32, 8, 8 and 64-fold higher, respectively (Table 2).

Molecular characterization of the uncommon resistance phenotype

178 PCR experiments for the detection of acquired genes putatively involved in MLS
179 resistance as well as uncommon acquired resistance patterns were all negative and
180 no mutation was found in L3, L4 and L22 ribosomal protein-encoding genes.
181 Interestingly, the strain displayed a point mutation in the *rrl* gene at an unexpected
182 position. Indeed, a nucleotide transition was found at position 2062 (*E. coli*
183 numbering) (A2062C) as shown in figure 1A. Considering that *S. constellatus*
184 harbored four copies of the ribosomal operon we assessed if the mutation affected
185 one or several *rrl* operons. The ARMS qPCR technique was used and confirmed the
186 presence of the A2062C mutation in more than a single copy of the 23S rRNA gene
187 in the strain UCN96. When DNA extracted from the resistant strain UCN96 was used
188 as template, cycle threshold (CT) obtained with the set of mismatches primers
189 appeared sooner (e.g. fourteen times), than the CT obtained with the set of primers
190 designed with the wild type sequence of the *rrl* operon (Figure 1B right). Inversely,
191 when the DNA extracted from the susceptible strain was used as template, only a six
192 CT difference was observed between the two sets of primers in favor of the
193 unmismatches primers (Figure 1B left). Such results, allow us to strongly suggest
194 that the point mutation A2062C was present in more than one 23S rRNA operon
195 copy.

Discussion

S. constellatus can be found as a part of the oral cavity and upper respiratory tract flora but can be also responsible for various pyogenic infections where a therapeutic management is required¹. β -lactams are the first-line molecules recommended for the treatment of streptococcal infections but in patients intolerant to that class of antibiotics, MLS antimicrobials constitute an alternative therapy.

The target site for MLS molecules is the 50S ribosomal subunit¹² and many cases of MLS resistance could be linked with an alteration by methylation of 23S rRNA at positions 2058 and/or 2059^{3,6}. In bacteria harboring several rRNA operon copies (such as *Staphylococcus* spp., *Streptococcus* spp. or *Enterococcus* spp.) the most prevalent mechanism for MLS resistance is an acquired mechanism consisting in expression of *erm* gene encoding methyltransferase or active efflux of the antibiotics encoded by the *mef* gene^{3,7,13,14}. Point mutations in 23S rRNA have been reported and appeared at specific positions of the domain V especially in pathogens harboring only 1 or 2 rRNA operon copies, such as mycoplasma with a prevalence in *Mycoplasma genitalium* estimated around 50%¹⁵. These mutations, regarding the species and nucleotide substitution, conferred different phenotypes of resistance. To our best knowledge, MLS resistance linked to these types of mutations seemed to be less prevalent in Gram-positive bacteria likely because they harbored a higher number of rRNA operons (4 *rrn* operons in streptococci or enterococci for example) and appeared generally at position 2058, 2059 or 2611, according to the species involved⁷. Interestingly, in our *S. constellatus* clinical isolate, the mutation found (A2062C) seemed to be very uncommon since it has been reported only once in a spiramycin- and streptogramin-resistant strain of *Streptococcus pneumoniae* and in a chloramphenicol-resistant *Halobacterium halobium*^{16,17,18}. Surprisingly, whereas *H.*

halobium harbored a single copy of rRNA operon, *S. pneumoniae* harbored 4 copies (like *S. constellatus*) and the mutation was found in the four copies of this operon^{16,18,19}. Our data were in accordance with these observations since several copies of *rrl* operon seemed altered in *S. constellatus* UCN96. Then, clinical isolates of viridans streptococci that harbored this unusual phenotype of resistance (susceptibility to 14-15 membered macrolides and lincosamides, resistance to 16-membered macrolides and streptogramins) has not been reported yet. Moreover, as previously described by different studies concerning the crystal structure of the interaction area of MLS antibiotics with 50S SU, amino acids modification in position 2062 (transition to a nonpolar to a polar amino acid) possibility changed hydrogen links between MLS antibiotics and their target in 50S SU of *Staphylococcus aureus* ribosome. As a consequence, resistance to different MLS antibiotics should be explained by this conformational variation²⁰.

As a conclusion, we have identified and characterized a point mutation (A2062C) found in more than one locus of the domain V of 23S rRNA that confers spiramycin and streptogramins resistance in *S. constellatus* isolated from a patient suffering of radionecrosis wound and treated with pristinamycin. Since *S. constellatus* is part of the oral cavity and upper respiratory tract flora and that irradiation is largely use in head and neck cancers, these data suggest that in clinical strains of SMG in patients that previously received MLS therapy, it would be wise to follow the susceptibility of the strain concerning all the MLS class of drugs (e.g. 14-, 15- and 16- membered macrolide, ketolide and also to lincosamide and streptogramins).

245 **Author Disclosure Statement**

246 The authors declare that they have no conflicts of interest.

247

248 **Funding**

249 This work was supported by a grant from the Ministère de l'Enseignement Supérieur
250 et de la Recherche to EA4655, Université de Caen Normandie, France.

251

References

1. **Gossling, J.** 1988. Occurrence and pathogenicity of the *Streptococcus milleri* group. Rev. Infect. Dis. 10:257–285.
2. **Limia, A., M.L. Jiménez, T. Alarcón, and M. López-Brea.** 1999. Five-year analysis of antimicrobial susceptibility of the *Streptococcus milleri* group. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 18:440–444.
3. **Leclercq, R.** 2002. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 34:482–492.
4. **Cattoir, V., L. Merabet, P. Legrand, C.-J. Soussy, and R. Leclercq.** 2007. Emergence of a *Streptococcus pneumoniae* isolate resistant to streptogramins by mutation in ribosomal protein L22 during pristinamycin therapy of pneumococcal pneumonia. J. Antimicrob. Chemother. 59:1010–1012.
5. **Bingen, E., R. Leclercq, F. Fitoussi, N. Brahimi, B. Malbruny, D. Deforche, and R. Cohen.** 2002. Emergence of group A Streptococcus strains with different mechanisms of macrolide resistance. Antimicrob. Agents Chemother. 46:1199–1203.
6. **Weisblum, B.** 1995. Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother. 39:577–585.
7. **Vester, B., and S. Douthwaite.** 2001. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob. Agents Chemother. 45:1–12.
8. **Malbruny, B., A. Canu, B. Bozdogan, B. Fantin, V. Zarrouk, S. Dutka-Malen, C. Feger, and R. Leclercq.** 2002. Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in *Staphylococcus aureus*. Antimicrob. Agents

275 Chemother. 46:2200–2207.

276 9. **Poyart, C., G. Quesne, S. Coulon, P. Berche, and P. Trieu-Cuot.** 1998.
277 Identification of Streptococci to species level by sequencing the gene encoding the
278 manganese-dependent superoxide dismutase. J. Clin. Microbiol. 36:41–47.

279 10. **Newton, C.R., A. Graham, L.E. Heptinstall, S.J. Powell, C. Summers, N.**
280 **Kalsheker, J.C. Smith, and A.F. Markham.** 1989. Analysis of any point mutation in
281 DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res.
282 17:2503–2516.

283 11. **Ye, S., S. Dhillon, X. Ke, A.R. Collins, and I.N. Day.** 2001. An efficient
284 procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res.
285 29:E88-88.

286 12. **Wilson, D.N.** 2014. Ribosome-targeting antibiotics and mechanisms of
287 bacterial resistance. Nat. Rev. Microbiol. 12:35–48.

288 13. **Roberts, M.C.** 2008. Update on macrolide-lincosamide-streptogramin,
289 ketolide, and oxazolidinone resistance genes. FEMS Microbiol. Lett. 282:147–159.

290 14. **Lucier, T.S., K. Heitzman, S.K. Liu, and P.C. Hu.** 1995. Transition mutations
291 in the 23S rRNA of erythromycin-resistant isolates of *Mycoplasma pneumoniae*.
292 Antimicrob. Agents Chemother. 39:2770–2773.

293 15. **Deguchi, T., M. Yasuda, K. Horie, K. Seike, M. Kikuchi, K. Mizutani, T.**
294 **Tsuchiya, S. Yokoi, M. Nakano, and S. Hoshina.** 2015. Drug resistance-associated
295 mutations in *Mycoplasma genitalium* in female sex workers, Japan. Emerg. Infect.
296 Dis. 21:1062–1064.

297 16. **Tait-Kamradt, A., T. Davies, P.C. Appelbaum, F. Depardieu, P. Courvalin,**

J. Petitpas, L. Wondrack, A. Walker, M.R. Jacobs, and J. Sutcliffe. 2000. Two new mechanisms of macrolide resistance in clinical strains of *Streptococcus pneumoniae* from Eastern Europe and North America. Antimicrob. Agents Chemother. 44:3395–3401.

17. Depardieu, F., and P. Courvalin. 2001. Mutation in 23S rRNA responsible for resistance to 16-Membered macrolides and streptogramins in *Streptococcus pneumoniae*. Antimicrob. Agents Chemother. 45:319–323.

18. Mankin, A.S., and R.A. Garrett. 1991. Chloramphenicol resistance mutations in the single 23S rRNA gene of the archaeon *Halobacterium halobium*. J. Bacteriol. 173:3559–3563.

19. Klappenbach, J.A., P.R. Saxman, J.R. Cole, and T.M. Schmidt. 2001. *rrndb*: the ribosomal RNA operon copy number database. Nucleic Acids Res. 29:181–184.

20. Matzov, D., Z. Eyal, R.I. Benhamou, M. Shalev-Benami, Y. Halfon, M. Krupkin, E. Zimmerman, H. Rozenberg, A. Bashan, M. Fridman, and A. Yonath. 2017. Structural insights of lincosamides targeting the ribosome of *Staphylococcus aureus*. Nucleic Acids Res. 45:10284–10292.

Legend of the figure

Figure 1. A) Partial nucleotide sequence alignment of 23S rRNA (*rrl*) encoding gene. Mutation at position 2062 is framed in bold line (*E. coli* numbering). B Left) RT-PCR results curves showing CT difference between wild-type (WT) primers vs ARMS

322 mismatches primers for a MLS susceptible strain of *S. constellatus* 13422 and the
323 resistant strain UCN96. Green lines corresponding to amplification when using WT
324 primers and red line corresponding to amplification when using mismatches primers.

A)

23S_	<i>S. constellatus</i> UCN96	CGGAAAGCCCCATGGAGCTTTACTGCAGTTTGATATTGAGTGTCTGTACCACATGTACA
23S_	<i>S. constellatus</i> 1050	CGGAAAGCCCCATGGAGCTTTACTGCAGTTTGATATTGAGTGTCTGTGCCACATGTACA
23S_	<i>S. pneumoniae</i>	CGGAAAGCCCCATGGAGCTTTACTGCAGTTTGATATTGAGTGTCTGTACCACATGTACA
23S_	<i>E. coli</i>	CGGAAAGCCCCGTGAACCTTTACTATAGCTTGACACTGAACATTGAGCCTTGATGTGTA

2062

B)

S. constellatus 13422

S. constellatus UCN96

Table 1. Primers used in this study

Gene (ribosomal protein)	Primer		Purpose
	Designation	Sequence (5' to 3')	
<i>rplC</i> (L3)	L3-F	CGCCCTTGGTATCTTAATCT	Detection of point mutation in
	L3-R	CTTCACCAGCTTCTTTACCAG	L3 protein
<i>rplD</i> (L4)	L4-F	GTGCCTGGTGCTAAGAAATC	Detection of point mutation in
	L4-R	TCTTCAAGAAGAGCCATTGA	L4 protein
<i>rplV</i> (L22)	L22-F	CACAAGCTTGGTGAGTTTGC	Detection of point mutation in
	L22-R	TACCATTGTCATCCAGTC	L22 protein
<i>rrl</i> (23S rRNA) domain V	23S-F	CGAAATTCCTTGTCGGGTAA	Detection of point mutation in
	23S-R	CCGTAGATGATCAACCTAC	domain V of 23S rRNA
<i>rrl</i> (23S rRNA) domain V	23S_ARMS_WT_F1	CGCGACAGGACGGAAAGA	Allelic determination of point mutation in 23S rRNA (ARMS)
	23S_ARMS_WT_F2	CGCGACAGGACGGAATGA	
	23S_ARMS_Mut_F1	CGCGACAGGACGGAAAGC	
	23S_ARMS_Mut_F2	CGCGACAGGACGGAATGC	
	23S_ARMS_R	ATCCCAACATCGCCTCCATC	

Table 2. MICs of MLS antibiotics and Chloramphenicol used in this study

Strains	MIC (µg/ml)											
	Macrolides					Lincosamides		Streptogramins			Phenicol	
	ERY	TEL	AZI	SPI	JOS	LIN	CLI	DAL	QUI	QD	PRI	CHL
<i>S. constellatus</i> 13422	<0.01	<0.01	0.06	0.06	0.06	0.5	0.03	2	1	0.5	0.12	2
<i>S. constellatus</i> UCN96	0.03	<0.01	0.12	≥256	32	1	0.06	≥64	8	4	8	8
<i>S. aureus</i> 29213	0.25	0.06	1	8	2	1	0.25	4	2	0.5	0.25	8
<i>S. pneumoniae</i> 49619	0.06	<0.01	0.12	0.25	0.06	0.5	0.06	16	1	0.25	0.12	2

ERY, Erythromycin ; TEL, Telithromycin ; AZI, Azithromycin ; SPI, Spiramycin ; JOS, Josamycin ; LIN, Lincomycin; CLI, Clindamycin;

DAL, Dalfopristin; QUI, Quinupristin; Q-D, Quinupristin-Dalfopristin; PRI, Pristinamycin ; CHL, Chloramphenicol.